Tailoring co-assembly loading of doxorubicin in solvent-triggering gel

Zhao, Chengcheng; Wang, Yanyao; Shi, Bofang; Li, Mingtao; Yan, Wei; Yang, Honghui

doi:10.1016/j.jcis.2022.06.175

Cited by 6 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once mixing this peptide with methotrexate (MTX), the complementary hydrogen bonding interaction between cyanuric acid in peptide and MTX would facilitate the increase of hydrophobicity of the system, thus leading to peptide/MTX nanostructures 88 . Yang et al employed the co-assembled strategy to fabricated doxorubicin-loaded gel, both the hydrogen bond and aromatic π-π stacking played the critical role in the co-assembly process 89 .…”

Section: Driving Forces For Co-assemblymentioning

confidence: 99%

Peptide-drug co-assembling: A potent armament against cancer

Wu,

Wang,

Sun

et al. 2023

Theranostics

View full text Add to dashboard Cite

Cancer is still one of the major problems threatening human health and the therapeutical efficacies of available treatment choices are often rather low. Due to their favorable biocompatibility, simplicity of modification, and improved therapeutic efficacy, peptide-based self-assembled delivery systems have undergone significant evolution. Physical encapsulation and covalent conjugation are two common approaches to load drugs for peptide assembly-based delivery, which are always associated with drug leaks in the blood circulation system or changed pharmacological activities, respectively. To overcome these difficulties, a more elegant peptide-based assembly strategy is desired. Notably, peptide-mediated co-assembly with drug molecules provides a new method for constructing nanomaterials with improved versatility and structural stability. The co-assembly strategy can be used to design various nanostructures for cancer therapy, such as nanotubes, nanofibrils, hydrogels, and nanovesicles. Recently, these co-assembled nanostructures have gained tremendous attention for their unique superiorities in tumor therapy. This article describes the classification of assembled peptides, driving forces for co-assembly, and specifically, the design methodologies for various drug molecules in co-assembly. It also highlights recent research on peptide-mediated co-assembled delivery systems for cancer therapy. Finally, it summarizes the pros and cons of co-assembly in cancer therapy and offers some suggestions for conquering the challenges in this field.

show abstract

Section: Driving Forces For Co-assemblymentioning

confidence: 99%

Peptide-drug co-assembling: A potent armament against cancer

Wu,

Wang,

Sun

et al. 2023

Theranostics

View full text Add to dashboard Cite

show abstract

“…[18][19][20] It can successfully load DOX as presented in our previous work, showing high gelation efficiency (in 3 seconds) and efficient controlled release of DOX (12 h), as well as injectable and disassembly release abilities. 21 However, pure Fmoc-F gels still show weak gel strength. [22][23][24] Chemical modifications 25,26 have been made in Fmoc-F, achieving expected improvements of strength and sustained release, but they involved difficult and complex preparation procedures.…”

Section: Introductionmentioning

confidence: 99%

A co-assembly process for high strength and injectable dual network gels with sustained doxorubicin release performance

Zhao,

Wang,

et al. 2024

Soft Matter

Self Cite

View full text Add to dashboard Cite

show abstract

Low‐molecular‐weight gels from amino acid and peptide derivatives for controlled release and delivery

Giuri,

Cenciarelli,

Tomasini

2024

Journal of Peptide Science

View full text Add to dashboard Cite

Low‐molecular‐weight (LMW) gelators are a versatile class of compounds able to self‐assemble and to form supramolecular materials, such as gels. The use of LMW peptides to produce these gels shows many advantages, because of their wide structure tunability, the low‐cost and effective synthesis, and the in vivo biocompatibility and biodegradability, which makes them optimal candidates for release and delivery applications. In addition, in these materials, the binding of the hosts may occur through a variety of noncovalent interactions, which are also the main factors responsible for the self‐assembly of the gelators, and through specific interactions with the fibers or the pores of the gel matrix. This review aims to report LMW gels based on amino acid and peptide derivatives used for the release of many different species (drugs, fragrances, dyes, proteins, and cells) with a focus on the possible strategies to incorporate the cargo in these materials, and to demonstrate how versatile these self‐assembled materials are in several applications.

show abstract

Tailoring co-assembly loading of doxorubicin in solvent-triggering gel

Cited by 6 publications

References 43 publications

Peptide-drug co-assembling: A potent armament against cancer

Peptide-drug co-assembling: A potent armament against cancer

A co-assembly process for high strength and injectable dual network gels with sustained doxorubicin release performance

Low‐molecular‐weight gels from amino acid and peptide derivatives for controlled release and delivery

Contact Info

Product

Resources

About